DZD2269

DRUG2 trials

Sponsors

Dizal Pharmaceuticals

Conditions

Healthy VolunteersMetastatic Castration Resistant Prostate Cancer

Phase 1

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

TerminatedNCT04634344

Dizal PharmaceuticalsMetastatic Castration Resistant Prostate Cancer

Start: 2021-04-12End: 2022-05-05Updated: 2022-07-11

A Study of DZD2269 in Healthy Adult Participants

CompletedNCT04932005

Dizal PharmaceuticalsHealthy Volunteers

Start: 2021-06-29End: 2022-04-12Updated: 2022-07-01

Related Papers

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist

Journal of Experimental & Clinical Cancer Research2022-10-1424 citations

Clinical pharmacokinetic/pharmacodynamic relationship of DZD2269, a potent and selective A2aR antagonist designed to overcome high levels of adenosine induced immunosuppression.

Journal of Clinical Oncology2022-06-01